Cargando…
Von Willebrand Disease: An Overview
Most commonly inherited bleeding disorder, first described in Aland Islands by Erik von Willebrand. It occurs as a result of decrease in plasma levels or defect in von Willebrand factor which is a large multimeric glycoprotein. Monomers of this glycoprotein undergo N-glycosylation to form dimers whi...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224412/ https://www.ncbi.nlm.nih.gov/pubmed/22131616 http://dx.doi.org/10.4103/0250-474X.89751 |
_version_ | 1782217377891483648 |
---|---|
author | Bharati, K. Pavani Prashanth, U. Ram |
author_facet | Bharati, K. Pavani Prashanth, U. Ram |
author_sort | Bharati, K. Pavani |
collection | PubMed |
description | Most commonly inherited bleeding disorder, first described in Aland Islands by Erik von Willebrand. It occurs as a result of decrease in plasma levels or defect in von Willebrand factor which is a large multimeric glycoprotein. Monomers of this glycoprotein undergo N-glycosylation to form dimers which get arranged to give multimers. Binding with plasma proteins (especially factor VIII) is the main function of von Willebrand factor. The disease is of two forms: Inherited and acquired forms. Inherited forms are of three major types. They are type 1, type 2, and type 3; in which type 2 is sub-divided into 2A, 2B, 2M, 2N. Type 1 is more prevalent than all other types. Mucocutaneous bleeding is mild in type 1 whereas it is mild to moderate in types 2A, 2B, and 2M. Type 2N has similar symptoms of haemophilia. The pathophysiology of each type depends on the qualitative or quantitative defects in von Willebrand factor. The diagnosis is based on von Willebrand factor antigen, von Willebrand factor activity assay, FVIII coagulant activity and some other additional tests. Results should be analyzed within the context of blood group. von Willebrand factor multimer analysis is essential for typing and sub typing the disease. The management of the disease involves replacement therapy, non-replacement therapy and other therapies that include antifibrinolytics and topical agents. |
format | Online Article Text |
id | pubmed-3224412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-32244122011-11-30 Von Willebrand Disease: An Overview Bharati, K. Pavani Prashanth, U. Ram Indian J Pharm Sci Review Article Most commonly inherited bleeding disorder, first described in Aland Islands by Erik von Willebrand. It occurs as a result of decrease in plasma levels or defect in von Willebrand factor which is a large multimeric glycoprotein. Monomers of this glycoprotein undergo N-glycosylation to form dimers which get arranged to give multimers. Binding with plasma proteins (especially factor VIII) is the main function of von Willebrand factor. The disease is of two forms: Inherited and acquired forms. Inherited forms are of three major types. They are type 1, type 2, and type 3; in which type 2 is sub-divided into 2A, 2B, 2M, 2N. Type 1 is more prevalent than all other types. Mucocutaneous bleeding is mild in type 1 whereas it is mild to moderate in types 2A, 2B, and 2M. Type 2N has similar symptoms of haemophilia. The pathophysiology of each type depends on the qualitative or quantitative defects in von Willebrand factor. The diagnosis is based on von Willebrand factor antigen, von Willebrand factor activity assay, FVIII coagulant activity and some other additional tests. Results should be analyzed within the context of blood group. von Willebrand factor multimer analysis is essential for typing and sub typing the disease. The management of the disease involves replacement therapy, non-replacement therapy and other therapies that include antifibrinolytics and topical agents. Medknow Publications & Media Pvt Ltd 2011 /pmc/articles/PMC3224412/ /pubmed/22131616 http://dx.doi.org/10.4103/0250-474X.89751 Text en Copyright: © Indian Journal of Pharmaceutical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Bharati, K. Pavani Prashanth, U. Ram Von Willebrand Disease: An Overview |
title | Von Willebrand Disease: An Overview |
title_full | Von Willebrand Disease: An Overview |
title_fullStr | Von Willebrand Disease: An Overview |
title_full_unstemmed | Von Willebrand Disease: An Overview |
title_short | Von Willebrand Disease: An Overview |
title_sort | von willebrand disease: an overview |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224412/ https://www.ncbi.nlm.nih.gov/pubmed/22131616 http://dx.doi.org/10.4103/0250-474X.89751 |
work_keys_str_mv | AT bharatikpavani vonwillebranddiseaseanoverview AT prashanthuram vonwillebranddiseaseanoverview |